These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32200996)

  • 1. [PET imaging to study the functional impact of P-glycoprotein in neuropharmacokinetics].
    Marie S; Tournier N
    Therapie; 2020; 75(6):623-632. PubMed ID: 32200996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
    Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
    Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
    Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
    Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging the impact of blood-brain barrier disruption induced by focused ultrasound on P-glycoprotein function.
    Goutal S; Novell A; Leterrier S; Breuil L; Selingue E; Gerstenmayer M; Marie S; Saubaméa B; Caillé F; Langer O; Truillet C; Larrat B; Tournier N
    J Control Release; 2023 Sep; 361():483-492. PubMed ID: 37562557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [
    Mairinger S; Leterrier S; Filip T; Löbsch M; Pahnke J; Hernández-Lozano I; Stanek J; Tournier N; Zeitlinger M; Hacker M; Langer O; Wanek T
    J Cereb Blood Flow Metab; 2024 Jan; 44(1):142-152. PubMed ID: 37728771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parametric Imaging of P-Glycoprotein Function at the Blood-Brain Barrier Using k
    Breuil L; El Biali M; Vodovar D; Marie S; Auvity S; Bauer M; Goutal S; Rodrigo S; Langer O; Tournier N
    Mol Imaging Biol; 2023 Dec; 25(6):1135-1141. PubMed ID: 37801196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of P-glycoprotein on pulmonary disposition of the model substrate [
    Mairinger S; Hernández-Lozano I; Filip T; Löbsch M; Stanek J; Zeitlinger M; Hacker M; Tournier N; Wanek T; Ehrhardt C; Langer O
    Eur J Pharm Sci; 2023 Apr; 183():106404. PubMed ID: 36773747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?
    Breuil L; Marie S; Goutal S; Auvity S; Truillet C; Saba W; Langer O; Caillé F; Tournier N
    J Cereb Blood Flow Metab; 2022 Jan; 42(1):175-185. PubMed ID: 34496661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-Glycoprotein (ABCB1) Inhibits the Influx and Increases the Efflux of
    Auvity S; Caillé F; Marie S; Wimberley C; Bauer M; Langer O; Buvat I; Goutal S; Tournier N
    J Nucl Med; 2018 Oct; 59(10):1609-1615. PubMed ID: 29748235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease.
    Bartels AL; de Klerk OL; Kortekaas R; de Vries JJ; Leenders KL
    Curr Top Med Chem; 2010; 10(17):1775-84. PubMed ID: 20645917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Modeling of (
    García-Varela L; García DV; Kakiuchi T; Ohba H; Nishiyama S; Tago T; Elsinga PH; Tsukada H; Colabufo NA; Dierckx RAJO; van Waarde A; Toyohara J; Boellaard R; Luurtsema G
    Mol Pharm; 2021 Jan; 18(1):416-428. PubMed ID: 33315404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance and Sensitivity of [
    Hernández-Lozano I; Leterrier S; Mairinger S; Stanek J; Zacher AS; Breyer L; Hacker M; Zeitlinger M; Pahnke J; Tournier N; Wanek T; Langer O
    Mol Pharm; 2024 Feb; 21(2):932-943. PubMed ID: 38225758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS.
    Elsinga PH; Hendrikse NH; Bart J; Vaalburg W; van Waarde A
    Curr Pharm Des; 2004; 10(13):1493-503. PubMed ID: 15134571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abundance of P-Glycoprotein and Other Drug Transporters at the Human Blood-Brain Barrier in Alzheimer's Disease: A Quantitative Targeted Proteomic Study.
    Storelli F; Billington S; Kumar AR; Unadkat JD
    Clin Pharmacol Ther; 2021 Mar; 109(3):667-675. PubMed ID: 32885413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET imaging to assess the impact of P-glycoprotein on pulmonary drug delivery in rats.
    Hernández-Lozano I; Mairinger S; Filip T; Sauberer M; Wanek T; Stanek J; Sake JA; Pekar T; Ehrhardt C; Langer O
    J Control Release; 2022 Feb; 342():44-52. PubMed ID: 34971693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of P-glycoprotein function at the human blood-brain barrier using [
    Mossel P; Arif WM; De Souza GS; Varela LG; van der Weijden CWJ; Boersma HH; Willemsen ATM; Boellaard R; Elsinga PH; Borra RJH; Dierckx RAJO; Lammertsma AA; Bartels AL; Luurtsema G
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3917-3927. PubMed ID: 37552369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.
    Syvänen S; Eriksson J
    ACS Chem Neurosci; 2013 Feb; 4(2):225-37. PubMed ID: 23421673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys.
    Liow JS; Kreisl W; Zoghbi SS; Lazarova N; Seneca N; Gladding RL; Taku A; Herscovitch P; Pike VW; Innis RB
    J Nucl Med; 2009 Jan; 50(1):108-15. PubMed ID: 19091890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
    Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
    J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition.
    Ke AB; Eyal S; Chung FS; Link JM; Mankoff DA; Muzi M; Unadkat JD
    J Nucl Med; 2013 Mar; 54(3):437-46. PubMed ID: 23359659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.